This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A second Look: Renal cell carcinoma (RCC), with focus on the recent ESMO presentation on the Phase 3 COSMIC-313 trial data from Exelixis. A trial evaluating the Cabometyx+Opdivo+Yervoy) triplet as 1st line for patients previously untreated
Ticker(s): EXELWho's the expert?
Institution: Private Practice
- Board certified medical oncologist and hematologist
- Expertise in breast cancer, head and neck cancer, lung cancer, leukemia
- Completed a number of oncology manuscripts and presentations
- Manages 56 patients with PNH and prescribed Epaveli to 29 patients
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
